Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Dai ichi Life Insurance Company Ltd

Dai ichi Life Insurance Company Ltd lessened its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 61.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 6,292 shares of the medical equipment provider’s stock after selling 10,000 shares during the period. Dai ichi Life Insurance Company Ltd’s holdings in Zimmer Biomet were worth $766,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of ZBH. Naples Money Management LLC acquired a new stake in Zimmer Biomet in the 4th quarter worth approximately $35,000. Activest Wealth Management grew its holdings in shares of Zimmer Biomet by 410.4% during the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 275 shares during the last quarter. Blue Trust Inc. increased its position in shares of Zimmer Biomet by 48.4% in the 4th quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock valued at $52,000 after acquiring an additional 153 shares during the period. Quent Capital LLC raised its stake in Zimmer Biomet by 21.6% in the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock worth $63,000 after acquiring an additional 92 shares during the last quarter. Finally, GAMMA Investing LLC acquired a new stake in Zimmer Biomet during the 4th quarter worth about $65,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH traded up $0.56 during trading on Friday, reaching $116.41. The stock had a trading volume of 1,084,246 shares, compared to its average volume of 1,315,878. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66. Zimmer Biomet Holdings, Inc. has a 1-year low of $102.00 and a 1-year high of $147.50. The stock has a market cap of $23.95 billion, a PE ratio of 25.20, a PEG ratio of 2.09 and a beta of 1.03. The business has a fifty day moving average price of $123.45 and a 200-day moving average price of $121.51.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.07. The firm had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. Zimmer Biomet’s quarterly revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the business posted $1.89 earnings per share. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Wednesday, June 26th will be given a $0.24 dividend. The ex-dividend date is Wednesday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 0.82%. Zimmer Biomet’s payout ratio is currently 20.78%.

Analyst Ratings Changes

Several research analysts have recently issued reports on ZBH shares. TheStreet upgraded Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday, February 8th. Canaccord Genuity Group reissued a “hold” rating and set a $130.00 price target on shares of Zimmer Biomet in a research report on Friday, February 23rd. StockNews.com downgraded shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a report on Monday, February 19th. Truist Financial reduced their price objective on Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating for the company in a research note on Friday, May 3rd. Finally, Evercore ISI lifted their price target on Zimmer Biomet from $125.00 to $130.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $134.40.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.